Avenue Historical Income Statement
| ATXI Stock | USD 2.15 0.09 4.37% |
Historical analysis of Avenue Therapeutics income statement accounts such as Depreciation And Amortization of 15.3 M, Interest Expense of 350.7 K or Selling General Administrative of 3.3 M can show how well Avenue Therapeutics performed in making a profits. Evaluating Avenue Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Avenue Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Avenue Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Avenue Therapeutics is a good buy for the upcoming year.
Avenue Therapeutics Net Income |
|
Avenue |
About Avenue Income Statement Analysis
Avenue Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Avenue Therapeutics shareholders. The income statement also shows Avenue investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Avenue Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Avenue Therapeutics. It is also known as Avenue Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Avenue Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Avenue Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.As of now, Avenue Therapeutics' EBITDA is increasing as compared to previous years. The Avenue Therapeutics' current Total Other Income Expense Net is estimated to increase to about 4.3 M, while Selling General Administrative is projected to decrease to under 3.3 M.
Avenue Therapeutics income statement Correlations
Click cells to compare fundamentals
Avenue Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Avenue Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Income | 357K | 62K | 7K | 20K | 126K | 165.9K | |
| Depreciation And Amortization | 26.3K | 5.2K | 7K | 8.0M | 14.5M | 15.3M | |
| Selling General Administrative | 3.1M | 2.3M | 2.5M | 5.3M | 4.2M | 3.3M | |
| Other Operating Expenses | 26.3M | 5.2M | 3.7M | 8.0M | 14.5M | 12.0M | |
| Operating Income | (26.3M) | (5.2M) | (3.7M) | (8.0M) | (14.5M) | (15.3M) | |
| Net Income From Continuing Ops | (25.9M) | (5.2M) | (3.7M) | (3.6M) | (10.5M) | (11.0M) | |
| Ebit | (26.3M) | (5.2M) | (3.7M) | (16.1M) | (10.5M) | (11.0M) | |
| Research Development | 23.2M | 2.9M | 1.3M | 2.7M | 10.4M | 8.7M | |
| Ebitda | (26.3M) | (5.2M) | (3.7M) | (8.0M) | 4.1M | 4.3M | |
| Total Operating Expenses | 26.3M | 5.2M | 3.7M | 8.0M | 14.5M | 12.0M | |
| Income Before Tax | (25.9M) | (5.2M) | (3.7M) | (3.6M) | (10.5M) | (11.0M) | |
| Total Other Income Expense Net | 357K | 62K | 7K | 4.4M | 4.1M | 4.3M | |
| Net Income Applicable To Common Shares | (21.5M) | (25.9M) | (5.2M) | (3.7M) | (3.4M) | (3.5M) | |
| Net Income | (25.6M) | (5.1M) | (3.7M) | 2.0M | (10.4M) | (10.9M) | |
| Income Tax Expense | (357K) | (62K) | (7K) | (5.7M) | (111K) | (116.6K) | |
| Net Interest Income | 357K | 62K | 7K | (1.1M) | (206K) | (216.3K) |
Currently Active Assets on Macroaxis
When determining whether Avenue Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avenue Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avenue Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avenue Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avenue Therapeutics. If investors know Avenue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avenue Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share 24.78 | Return On Assets (2.01) | Return On Equity (5.35) |
The market value of Avenue Therapeutics is measured differently than its book value, which is the value of Avenue that is recorded on the company's balance sheet. Investors also form their own opinion of Avenue Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avenue Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avenue Therapeutics' market value can be influenced by many factors that don't directly affect Avenue Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avenue Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avenue Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avenue Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.